The impact of VKORC1-1639G > A genetic polymorphism upon warfarin dose requirement in different ethnic populations

References

• Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003;13:247-52
   PubMedGoogle Scholar
• Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 2010;41:2705-13
   PubMed Web of Science ®Google Scholar
• Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93
   PubMed Web of Science ®Google Scholar
• Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011;364:1144-53
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006;79:291-302
   PubMed Web of Science ®Google Scholar
• Bazan NS, Sabry NA, Rizk A, et al. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Ir J Med Sci 2013: epub ahead of print. doi: 10.1007/s11845-013-0978-y
   Google Scholar
• Cen HJ, Zeng WT, Leng XY, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2010;70:234-40
   PubMed Web of Science ®Google Scholar
• Gan GG, Phipps ME, Lee MM, et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 2011;90:635-41
   PubMed Web of Science ®Google Scholar
• Gu Q, Kong Y, Schneede J, et al. VKORC1-1639G > A, CYP2C9, EPHX1691A > G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur J Clin Pharmacol 2010;66:1217-27
   PubMed Web of Science ®Google Scholar
• Kaur A, Khan F, Agrawal SS, et al. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G > A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement. Indian J Med Res 2013;137:203-9
   PubMed Web of Science ®Google Scholar
• Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007;120:181-6
   PubMed Web of Science ®Google Scholar
• Krishna Kumar D, Madhan S, Balachander J, et al. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thromb Res 2013;131:363-7
   PubMed Web of Science ®Google Scholar
• Kwon A, Jo SH, Im HJ, et al. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy. J Thromb Thrombolysis 2011;32:467-73
   PubMed Web of Science ®Google Scholar
• Lee MT, Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009;10:1905-13
   PubMed Web of Science ®Google Scholar
• Liang R, Li L, Li C, et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 2012;34:120-5
   PubMed Web of Science ®Google Scholar
• Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007;63:1135-41
   PubMed Web of Science ®Google Scholar
• Michaud V, Vanier MC, Brouillette D, et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther 2008;83:740-8
   PubMed Web of Science ®Google Scholar
• Momary KM, Shapiro NL, Viana MA, et al. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 2007;8:1535-44
   PubMed Web of Science ®Google Scholar
• Namazi S, Azarpira N, Hendijani F, et al. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther 2010;32:1050-60
   PubMed Web of Science ®Google Scholar
• Nakamura K, Obayashi K, Araki T, et al. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther 2012;37:481-5
   PubMed Web of Science ®Google Scholar
• Obayashi K, Nakamura K, Kawana J, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006;80:169-78
   PubMed Web of Science ®Google Scholar
• Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 2009;65:1097-103
   PubMed Web of Science ®Google Scholar
• Oner Ozgon G, Langaee TY, Feng H, et al. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 2008;64:889-94
   PubMed Web of Science ®Google Scholar
• Ozer N, Cam N, Tangurek B, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels 2010;25:155-62
   PubMed Web of Science ®Google Scholar
• Özer M, Demirci Y, Hizel C, et al. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Basic Clin Pharmacol Toxicol 2013;112:209-14
   PubMed Web of Science ®Google Scholar
• Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010;87:57-64
   PubMed Web of Science ®Google Scholar
• Santos PC, Dinardo CL, Schettert IT, et al. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol 2013;69:789-97
   PubMed Web of Science ®Google Scholar
• Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33
   PubMed Web of Science ®Google Scholar
• Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011;21:130-5
   PubMed Web of Science ®Google Scholar
• Shrif NE, Won HH, Lee ST, et al. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 2011;67:1119-30
   PubMed Web of Science ®Google Scholar
• Smires FZ, Moreau C, Habbal R, et al. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. J Clin Pharm Ther 2012;37:594-8
   PubMed Web of Science ®Google Scholar
• Tatarūnas V, Lesauskaitė V, Veikutienė A, et al. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement. Medicina 2011;47:25-30
   PubMed Web of Science ®Google Scholar
• Teh LK, Langmia IM, Fazleen Haslinda MH, et al. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. J Clin Pharm Ther 2012;37:232-6
   PubMed Web of Science ®Google Scholar
• Yoshizawa M, Hayashi H, Tashiro Y, et al. Effect of VKORC1-1639 G > A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 2009;124:161-6
   PubMed Web of Science ®Google Scholar
• Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745-51
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP2C9 genotypes. Clin Chem 2007;53:1199-205
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008;47:565-94
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Spreafico M, Siboni SM, et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004;75:198-203
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92
   PubMed Web of Science ®Google Scholar
• Yang L, Ge W, Yu F, et al. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta-analysis. Thromb Res 2010;125:e159-66
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008
   PubMed Web of Science ®Google Scholar